肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

ASCO 2013：多靶点药物Pazopanib维持治疗延缓晚期卵巢癌复发

2013-06-02 MedSci MedSci原创

Pazopanib卵巢癌Votrient
关注

    美国临床肿瘤学会（ASCO）2013年年会公布的一项针对晚期卵巢癌妇女的III期临床试验发现：与口服安慰剂相比，患者初始化疗成功后予以口服靶向药物pazopanib (Votrient)的无病生存期平均延长5.6个月。    在发达国家，卵巢癌在导致女性死亡的肿瘤中排第五位。晚期卵巢癌是侵袭性疾病，其治愈率只有20-25%。尽管以手术和放疗

    美国临床肿瘤学会（ASCO）2013年年会公布的一项针对晚期卵巢癌妇女的III期临床试验发现：与口服安慰剂相比，患者初始化疗成功后予以口服靶向药物pazopanib (Votrient)的无病生存期平均延长5.6个月。
    在发达国家，卵巢癌在导致女性死亡的肿瘤中排第五位。晚期卵巢癌是侵袭性疾病，其治愈率只有20-25%。尽管以手术和放疗为主的初治会获得成功，但约70%的晚期卵巢癌患者的肿瘤会复发，其中半数的复发是在第一年内。肿瘤复发后，患者不得不重新开始激进的治疗。目前尚无预测患者复发风险的检测项目，所以绝大多数患者接受例如pazopanib的维持治疗。
    这项研究的近期目标是根据患者个体和肿瘤特点，联合pazopanib和其他靶向药物以及个体化治疗。
     “我们的发现显示我们终于拥有了维持已通过初治实现的控制卵巢癌生长的药物。”德国艾森Kliniken Essen Mitte妇科肿瘤学教授Andreas du Bois医学博士如是说。“如果pazopanib被批准用于卵巢癌，很多患者将会拥有更长的无病生存期和无需接受化疗时间。在这些时间里，患者维持对肿瘤控制，而不是肿瘤掌控患者的生命”。
    Pazopanib是一种口服药物，能阻断参与肿瘤生长和血管生成（血管发生）的多个靶点。在这项研究中，940例III/IV期的卵巢癌、输卵管癌和原发腹膜癌患者随机每日口服Pazopanib或安慰剂24个月。所有患者均有手术史和5轮或更多周期的化疗，有效地阻止了疾病恶化。患者平均随访时间是
24个月。Pazopanib组和安慰剂组患者的出现疾病恶化（无进展生存期）的中位时间分别是17.9和12.3个月。
   “晚期卵巢癌妇女的肿瘤复发仍是很常见的。这项大规模的试验显示针对多种分子肿瘤的驱动因子治疗会严重影响肿瘤的生长，使得患者服用药物后的无病生存时间明显延长。这项研究提供了活生生的例子：肿瘤研究的精准医学时代正在不存在替代批准药物的领域取得成功”。ASCO发言人和妇科肿瘤专家Carol Aghajanian博士说。

相关信息：
    Pazopanib 已经被FDA批准用于治疗肾癌和软组织肉瘤。属于多靶点抑制剂，主要针对酪氨酸激酶，能抑制VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, c-kit，从而抑制肿瘤生长和血管新生。不过也有研究认为它对NSCLC也有很好的疗效。
与ASCO2013相关的拓展阅读：


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1721957, encodeId=88aa1e219572c, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Sat Mar 08 11:39:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938219, encodeId=850e19382197d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 14 00:39:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714694, encodeId=0a611e146941c, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sun Sep 22 10:39:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5973, encodeId=cda459e3f6, content=卵巢癌患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=米米, createdTime=Mon Jul 29 16:10:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394538, encodeId=9e9e1394538d4, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Tue Jun 04 11:39:00 CST 2013, time=2013-06-04, status=1, ipAttribution=)]
    2014-03-08 zhangph

    #多靶点#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1721957, encodeId=88aa1e219572c, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Sat Mar 08 11:39:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938219, encodeId=850e19382197d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 14 00:39:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714694, encodeId=0a611e146941c, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sun Sep 22 10:39:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5973, encodeId=cda459e3f6, content=卵巢癌患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=米米, createdTime=Mon Jul 29 16:10:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394538, encodeId=9e9e1394538d4, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Tue Jun 04 11:39:00 CST 2013, time=2013-06-04, status=1, ipAttribution=)]
    2013-09-14 quxin068

    #ASC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1721957, encodeId=88aa1e219572c, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Sat Mar 08 11:39:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938219, encodeId=850e19382197d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 14 00:39:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714694, encodeId=0a611e146941c, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sun Sep 22 10:39:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5973, encodeId=cda459e3f6, content=卵巢癌患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=米米, createdTime=Mon Jul 29 16:10:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394538, encodeId=9e9e1394538d4, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Tue Jun 04 11:39:00 CST 2013, time=2013-06-04, status=1, ipAttribution=)]
    2013-09-22 12498e5fm22(暂无昵称)

    #AZ#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1721957, encodeId=88aa1e219572c, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Sat Mar 08 11:39:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938219, encodeId=850e19382197d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 14 00:39:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714694, encodeId=0a611e146941c, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sun Sep 22 10:39:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5973, encodeId=cda459e3f6, content=卵巢癌患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=米米, createdTime=Mon Jul 29 16:10:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394538, encodeId=9e9e1394538d4, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Tue Jun 04 11:39:00 CST 2013, time=2013-06-04, status=1, ipAttribution=)]
    2013-07-29 米米

    卵巢癌患者

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1721957, encodeId=88aa1e219572c, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Sat Mar 08 11:39:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938219, encodeId=850e19382197d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 14 00:39:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714694, encodeId=0a611e146941c, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sun Sep 22 10:39:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5973, encodeId=cda459e3f6, content=卵巢癌患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=米米, createdTime=Mon Jul 29 16:10:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394538, encodeId=9e9e1394538d4, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Tue Jun 04 11:39:00 CST 2013, time=2013-06-04, status=1, ipAttribution=)]
    2013-06-04 siiner

    #晚期卵巢癌#

    0